Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

LMN-201 for forebygging av tilbakefall av C. Difficile-infeksjon

1. oktober 2026 oppdatert av: Lumen Bioscience, Inc.

En fase 2, randomisert, dobbeltblind, placebokontrollert studie av LMN-201 for forebygging av tilbakefall av C. Difficile-infeksjon

This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

375

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Escondido, California, Forente stater, 90027
        • Kaiser Permanente
    • Connecticut
      • Hamden, Connecticut, Forente stater, 06518
        • Gastroenterology Center of Connecticut
    • Florida
      • Tampa, Florida, Forente stater, 33606
        • University of South Florida
    • Illinois
      • Burr Ridge, Illinois, Forente stater, 60527
        • Metro Infectious Disease Consultants, LLC
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40503
        • Baptist Health Research
    • Michigan
      • Detroit, Michigan, Forente stater, 48202
        • Henry Ford Health System
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • University of Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Mayo Clinic - Rochester
    • New York
      • New York, New York, Forente stater, 10021
        • Weill Cornell Medicine
    • North Carolina
      • Mount Airy, North Carolina, Forente stater, 27030
        • IMA Clinical Research
    • Texas
      • Houston, Texas, Forente stater, 77030
        • MD Anderson Cancer Center
    • Virginia
      • Annandale, Virginia, Forente stater, 22003
        • Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC
      • Charlottesville, Virginia, Forente stater, 22903
        • University of Virginia School of Medicine
      • Springfield, Virginia, Forente stater, 22015
        • Kaiser Permanente-Mid Atlantic
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53792
        • UW Health University Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male or female, aged 18 or older.
  2. Diagnosis of CDI defined as a new or recent history of 3 or more bowel movements per day with a loose or watery consistency (Bristol Stool Scale 5, 6, or 7); a positive stool C. difficile toxin B immunoassay (stool collected no more than 7 days before first dose of LMN-201/placebo), and no other likely explanation for diarrhea. NOTE: Diarrhea is not required to be present on the day of enrollment.
  3. Provision of signed and dated informed consent form.
  4. Scheduled to receive or planning to receive a ≤28-day course of SOC antibiotic therapy for CDI. Participant must have been diagnosed with CDI for 7 or fewer days at time of initial study drug administration. SOC antibiotic therapy is defined as the receipt of oral fidaxomicin or oral metronidazole or oral vancomycin (see Section 8.2.6)
  5. May be on systemic antibiotics for an infection unrelated to the gastrointestinal tract.
  6. Ability to take oral medication and willingness to adhere to the study medication regimen.
  7. Stated willingness and ability to comply with all study procedures and availability for the duration of the study and investigator believes individual will complete the study.
  8. Access to a mobile smartphone.
  9. For females of reproductive potential: use of highly effective contraception for at least 4 weeks prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of study drug administration.
  10. For males of reproductive potential: agreement to use condoms or other methods to ensure effective contraception with partner during study participation and for an additional 4 weeks after the end of study drug administration.

Exclusion Criteria:

  1. Fulminant C. difficile colitis.

  2. Admitted or expect to be admitted to an intensive care unit.

  3. Underlying gastrointestinal disorder characterized by diarrhea including but not limited to chronic ulcerative colitis, Crohn's disease, celiac sprue, short bowel syndrome, dumping syndrome following gastrectomy, pancreatic insufficiency, enteric parasitic infection, viral enteritis, bacterial enteritis (salmonella, shigella, ETEC, etc.).

  4. Neutropenia (absolute neutrophil count of < 1000 per microliter for any reason).

  5. Current or previous treatment in past 3 months with any therapy likely to influence the outcome of this study, including but not limited to the following:

    1. Bezlotoxumab (Zinplava, Merck & Co.), or another antibody against C. difficile toxin(s)
    2. C. difficile vaccine
    3. SER-109 (Seres Therapeutics)
    4. CP101 (Finch Therapeutics)
    5. VE303 (Vedanta Therapeutics)
    6. Fecal microbiota transplant
    7. Current therapy with oral exchange resins
    8. Protracted exposure to mu-agonist opioids and/or anticholinergic medication prescribed for diarrheal symptoms (unable to stop mu-agonist opioid treatment unless on a stable dose as of onset of diarrhea and no increase in dose planned for the duration of the study.)
  6. Treatment with SOC antibiotic therapy is planned for longer than a 28-day period.

  7. Pregnancy, anticipated pregnancy, or breastfeeding.

  8. Inability or unwillingness to swallow numerous, relatively large capsules containing study drug or placebo because of a swallowing disorder or dysphagia.

  9. Inability to pass swallowed capsules into the distal small intestine because of gastroparesis, repetitive vomiting, or anatomic narrowing in the esophagus, stomach, or small intestine.

  10. Psychiatric illness that would affect compliance with medications, study capsules, or follow-up.

  11. Status as an inmate, residential mental health program, or residential substance abuse program.

  12. Terminal illness with limited life expectancy of less than 24 weeks.

  13. Poor concurrent medical risks with clinically significant co-morbid disease such that, in the opinion of the investigator, the patient should not be enrolled.

  14. Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the individual, would make it unlikely for the individual to complete the study, or would confound the results of the study.

    • Note: Use of probiotics and other food supplements (e.g., yogurt, kefir, kimchi, etc.) are not exclusionary.
    • Note: Assuming participants meet all of the inclusion criteria and none of the exclusion criteria, participants with underlying malignancy with a good life expectancy in the study are not excluded.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.

Eksperimentell: Sentinel Cohort

LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:

  • 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile
  • 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism
Aktiv komparator: LMN-201

LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:

  • 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile
  • 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Proportion of participants who achieve global cure
Tidsramme: Up to 16 weeks after initiation of therapy

Proportion of total participants with both successful initial CDI treatment and no CDI recurrence during the Prevention and Observation Phases (by treatment assignment).

Up to 16 weeks after initiation of therapy

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. august 2024

Primær fullføring (Faktiske)

31. august 2026

Studiet fullført (Antatt)

1. desember 2026

Datoer for studieregistrering

Først innsendt

8. april 2022

Først innsendt som oppfylte QC-kriteriene

8. april 2022

Først lagt ut (Faktiske)

15. april 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CDI02
  • CDMRP-PR221885 (Annet stipend/finansieringsnummer: CDMRP)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .